Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) FCF Margin (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed FCF Margin for 9 consecutive years, with 3365.07% as the latest value for Q4 2025.

  • Quarterly FCF Margin changed N/A to 3365.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 109.63% through Dec 2025, changed N/A year-over-year, with the annual reading at 109.63% for FY2025, N/A changed from the prior year.
  • FCF Margin hit 3365.07% in Q4 2025 for Seres Therapeutics, down from 626.21% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 626.21% in Q3 2025 to a low of 18929.68% in Q3 2023.
  • Historically, FCF Margin has averaged 3906.96% across 4 years, with a median of 1229.35% in 2021.
  • Biggest YoY gain for FCF Margin was 559308bps in 2023; the steepest drop was -1731731bps in 2023.
  • Year by year, FCF Margin stood at 846.32% in 2021, then crashed by -556bps to 5549.44% in 2022, then skyrocketed by 101bps to 43.64% in 2023, then plummeted by -7810bps to 3365.07% in 2025.
  • Business Quant data shows FCF Margin for MCRB at 3365.07% in Q4 2025, 626.21% in Q3 2025, and 43.64% in Q4 2023.